Randomized trials comparing Telmisartan vs. Valsartan and Losartan 24-hour ambulatory blood pressure control, GLP-1 heart failure outcomes, UKPDS 34 cardiovascular mortality reductions, and statin + ezetimibe ApoB targets. Explore 714 indexed studies and multi-trial syntheses with verified PubMed PMIDs, participant sample sizes (N), and Absolute vs. Relative Risk numbers.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
MACiTEPH was discontinued for futility, as no treatment effect on 6MWD (primary endpoint) was observed.
CETP inhibitors evacetrapib and torcetrapib increase apoA1 in HDL subspecies that contain apoC3 and other HDL subspecies associated with higher risk of coronary heart disease.
Telmisartan/rosuvastatin SPC therapy was more effective in lowering central BP compared with the telmisartan single-drug treatment.
These findings do not support the hypothesis that elevated baseline inflammatory markers predict poor response to sertraline in patients with CHD and major depression.
Results of the study highlight that vildagliptin and empagliflozin have a significant beneficial effect in reducing HbA1c, fasting blood glucose, systolic blood pressure, and weight of participants.
After treatment, the LAD (test, 31.3±4.1mm; control, 36.2±4.6mm), hs-CRP (test, 3.1±1.9 mg/L; control, 5.2±2.3mg/L) levels, and AF recurrence times were markedly lower in the test group (22) compared with the control group (44).
These findings indicate that, despite similar BP-lowering effect, the addition of canrenone to valsartan/amlodipine combination was more effective in reducing UAE than HCTZ addition.
This study suggests that statin therapy results in variable effects on oxidative stress markers in hypercholesterolemic subjects.
The campesterol/cholesterol and β-sitosterol/cholesterol ratios were lower, whereas the desmosterol/cholesterol ratio was higher in patients receiving simvastatin/ezetimibe (P < 0.0001 vs rosuvastatin, for all).
Among subjects treated with highly effective lipid-lowering therapy, the intake of 25 g of fibers added favorable effects, mainly by reducing phytosterolemia.
Postoperative maximum NT-proBNP concentrations did not differ significantly between the groups (effect estimate: -64.51 ng.L -1 ; 95% CI -332.66 to 195.56; p = 0.61).
In type 2 diabetes patients with liver steatosis, treatment with semaglutide resulted in a significant improvement in fatty liver reduction when compared to placebo.
The patients whose alanine aminotransferase increasing more than upper normal limit in.
The combination of losartan and HCTZ is as effective as amlodipine plus ARB in improving LV relaxation in hypertensive patients.
A total of 109 participants were enrolled in the study, and there were no statistically significant differences in the baseline characteristics of.
T20/SA2.5 demonstrated superior BP-lowering efficacy and favorable tolerability compared with T40 in patients inadequately controlled on T20, supporting the value of early low-dose combination therapy.
Atorvastatin (10 mg/day) is more effective at lowering LDL cholesterol in hypercholesterolemic patients than cerivastatin (0.3 mg/day).
Our findings suggest 24 weeks of empagliflozin treatment was associated with an improvement in blood sugar control, irrespective of the baseline use of metformin therapy.
Getting both at the same time of ezetimibe with simvastatin, a dual inhibition treatment strategy targeting both cholesterol synthesis and absorption, is well tolerated and provides greater LDL-C-lowering efficacy than...
Both concentrations of the NO-donating bimatoprost NCX 470 lower IOP more than latanoprost following 2 weeks of daily therapy.
Of 102 randomized participants, 85 (83.3%) completed follow-up.
Although rosuvastatin/ezetimibe combination therapy had a greater LDL-C reduction effect than rosuvastatin single-drug treatment, it had no additional effects on insulin sensitivity and vascular inflammatory response.
Lipid-lowering therapy with simvastatin plus ezetimibe was associated with a better pattern of lipoprotein subfractions than rosuvastatin single-drug treatment.
Of 275 patients screened at 9 heart and blood vessel centers, 199 were enrolled (AML/LOS, n = 101; LOS/HCTZ, n = 98), and 183 completed the study.
The effect of combined use of atorvastatin and ezetimibe was better than atorvastatin alone, which can effectively reduce the blood lipid levels in diabetic patients with CHD and improve plaque stability.
The rs7069102 CC + CG genotype of SIRT1 may be associated with a reduced risk of CHD, whereas the association between the rs4746720 TC + TT genotype and CHD risk was only nominally significant and did not withstand correction for multiple comparisons.
These findings should be interpreted cautiously due to the exploratory design and small sample size. Larger studies are required to confirm efficacy and long-term outcomes.
Clinicians should exercise caution when prescribing such combinations, particularly in high-risk patients. Further large-scale studies are needed to better quantify risk across different statins and antibiotic classes.
In patients with recent ACS, hsCRP independently predicted MACE, while both hsCRP and IL-6 predicted death.
Walnut consumption may be associated with small reductions in CRP and IL-6 levels, without significant effects on TNF-α or adipokine concentrations. However, these effects are modest, and their clinical relevance remains uncertain.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
